JW (Cayman) Therapeutics Co (HKSE:02126) Total Assets : HK$2,347.4 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Total Assets?

JW (Cayman) Therapeutics Co's Total Assets for the quarter that ended in Dec. 2023 was HK$2,347.4 Mil.

During the past 12 months, JW (Cayman) Therapeutics Co's average Total Assets Growth Rate was -20.70% per year. During the past 3 years, the average Total Assets Growth Rate was -2.90% per year. During the past 5 years, the average Total Assets Growth Rate was 41.60% per year.

During the past 6 years, JW (Cayman) Therapeutics Co's highest 3-Year average Total Assets Growth Rate was 88.30%. The lowest was -2.90%. And the median was 50.60%.

Total Assets is connected with ROA %. JW (Cayman) Therapeutics Co's annualized ROA % for the quarter that ended in Dec. 2023 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. JW (Cayman) Therapeutics Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

JW (Cayman) Therapeutics Co Total Assets Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Total Assets Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

744.01

4,480.33

3,816.18

3,117.14

2,347.36

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial						3,816.18	3,393.53	3,117.14	2,901.12	2,347.36

JW (Cayman) Therapeutics Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

JW (Cayman) Therapeutics Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	1841.746	+	505.609
	=	2,347.4

JW (Cayman) Therapeutics Co's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	1841.746	+	505.609
	=	2,347.4

JW (Cayman) Therapeutics Co (HKSE:02126) Total Assets Explanation

Total Assets is connected with ROA %.

JW (Cayman) Therapeutics Co's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (2901.116	+	2347.356)	/ 2 )
	=	0	/	2624.236
	=	0.00 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

JW (Cayman) Therapeutics Co's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (2901.116	+	2347.356)	/ 2 )
=	0	/	2624.236
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

JW (Cayman) Therapeutics Co Total Assets Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines